Category Archives: Bladder problems

Four important points about Nova Cells Institute

cropped-nova-cells-bannerNova Cells Institute has never worked with embryonic or fetal stem cells, and never will. Embryonic and fetal stem cells can produce tumors (These are classified as pluripotent” which means they can form teratomas and other tumors in certain instances such as being injected into the central nervous system). The adult stem cells Nova Cells uses (umbilical cord, Wharton’s Jelly, placenta-derived, and a patient’s own bone marrow) are “multipotent” which limits the body cell types they can become (These stem cells do not form teratomas or such. Some private stem cell clinics in Europe and the US have injected adult stem cells into organs such as kidneys and eyes which caused problems and complications. Nova Cells Institute has never injected stem cells into an organ).
Let’s be very clear about these points and a few others:

(1) Nova Cells was established in 2009. There are other companies that came along later on which use “Nova” in their company title, but these are NOT affiliated in any way with Nova Cells Institute of Mexico (NCIM).

(2) Nova Cells Institute has never used embryonic or fetal stem cells and never will (They can form tumors under certain circumstances).

(3) Nova Cells Institute only uses multipotent adult stem cells derived from umbilical cord blood, Wharton’s Jelly, placental tissue, and a patient’s own bone marrow.

(4) Nova Cells Institute administers stem cells by intravenous drip (On rare occasions Nova Cells affiliated doctors recommend an intrathecal or spinal tap infusion of cells. Everything related to this is spelled out, a process called “informed consent”. Patients who prefer not to do this are given cells by intravenous or IV drip).

NOVA CELLS at-a-glance (2 pages)


NCIM promo flyer - COVER - 8-3-2017

https://ncimx.files.wordpress.com/2017/08/ncim-at-a-glance-2-page-document.pdf

 

COMPARING: What sets Nova Cells apart from all other stem cell treatment programs

compare-apples-oranges-free-morguefilehttps://ncimx.wordpress.com/comparing-what-sets-nova-cells-apart-from-all-other-stem-cell-treatment-programs/

Nova Cells Institute on the air! (Blog Talk Radio)

OLYMPUS DIGITAL CAMERAblog-talk-radioOn Wednesday, 1-18-2017 Nova Cell’s (NCIM) patient educator & care coordinator, Grace Odgers, PhD cand., was interviewed by Denise Messenger on Blog Talk Radio concerning NCIMs unique stem cell medicine program. You can access an audio of this 42m31s minute interview by clicking the link below.

//percolate.blogtalkradio.com/offsiteplayer?hostId=544015&episodeId=9755363

Quick read – NCIM Program

Abel working in biocabinetNova Cells Institute of Mexico contracted MDs treat children and adults with umbilical cord blood stem cells and in some instances a patient’s own bone marrow stem cells. MDs who work with Nova Cells also administer its proprietary “Beacon Factor“, a nontoxic compound that greatly enhances stem cell homing, improves circulation, reduces inflammation, improves nerve signal transmission, and steps up the processing of intracellular “junk” by lysosomes (The cells “garbage disposal” system whose malfunctioning is linked to all kinds of neurodegenerative diseases and conditions).

Nova Cells uses only certifiably disease free umbilical cord stem cells and those from Wharton’s Jelly, and sometimes a patient’s own bone marrow stem cells, all of which are processed in Mexico in a state-of-the-art laboratory run by our firm’s director of laboratory services, Dr. Abel Pena (Photo above).

Dr. Pena, who is a biochemist, was trained by a leading US stem cell biologist and maintains the highest levels of safety and hygiene in his lab in Tijuana. In addition, he has pioneered numerous methods for priming stem cells; that is, getting them to respond to chemical signals in target tissues by becoming cells that tend to effect or support healing or relief. Stem cells primed using his methods have produced impressive, sometimes remarkable clinical responses in people with a wide variety of neurologic & other diseases and conditions.

CONTACT: Grace Odgers, PhD cand. – Program educator and patient care coordinator

Phone: 1-562- 916-3410 E-mail: gracepatients@gmail.com

 THE NOVA CELLS DIFFERENCE

https://ncimexico.files.wordpress.com/2016/07/the-nova-cells-difference.pdf

CONDITIONS NOVA CELLS INSTITUTE HAS SUCCESSFULLY TREATED

https://ncimx.wordpress.com/conditions-nova-cells-has-successfully-treated/

 

 

Wharton’s Jelly Stem Cells: safety & more

stem cells from poweredtemplatesADVANTAGES OF WHARTON’S JELLY STEM CELLS ESPECIALLY MESENCYMALS (Designated as WJ-MSC for convenience below) ESPECIALLY WITH RESPECT TO SAFETY

WJ HAS MORE STEM CELLS THAN EITHER BONE MARROW OR ADIPOSE TISSUE

The quantity of mesenchymal stem cells which can typically be obtained from bone marrow is far less than that Wharton’s Jelly: 0.001 to 0.01% mononuclear cells from BM, with 1 g of adipose tissue yielding ~ 5 × 103 stem cells, and Wharton’s jelly 1 to 5 × 104 cells/cm of umbilical cord. In side-by-side comparison studies of MSC from bone marrow adipose tissue and Wharton’s jelly, WJ-MSCs had the highest proliferative capacity.

WJ STEM CELLS ARE MORE PRIMITIVE THAN OTHER ADULT STEM CELL TYPES YET DO NOT PRODUCE TUMORS AND ACTUALLY HAVE ANTI-TUMOR EFFECTS IN VITRO (Lab dish) AND IN VIVO (In living animals & humans)  

WJ-MSC differ from other adult MSCs with respect to the fact they demonstrate far more primitive characteristics e.g., they express embryonic-like stem cell markers including  pluripotency genes, Oct-4, Nanog, and SOX-2 but at levels well below that of embryonic stem (ESC) cells. Despite this, WJ-MSCs do not form tumors (teratomas). This is attributed to the fact that WJ-MS’s have a lower expression of pluripotency genes than embryonic stem cells (ESCs being very pluripotent and by virtue of this are prone to develop teratomas when injected into animals or humans). When WJ-MSCs were injected in immunocompromised and immunodeficient animals they still failed to form tumors.

Also: WJ-MSCs express low levels of the embryonic stem cell pluripotency markers POUF1, NANOG, SOX2 and LIN28, which also plays a role in the fact they do not produce teratomas. WJ-MSCs also synthesize and express several cytokines including IL12A which is associated with the induction of apoptosis (programmed cell death) which is believed to underlie their ability to lyse (eradicate) tumor cells.

Furthermore, the transcriptome of WJ-MSC and ESC differs substantially in that WJ-MSCs demonstrate high expression levels of several tumor suppressor genes and suppresses tumors both in vitro and in vivo. Moreover, large quantities of tumor growth inhibiting cytokines and growth factors are secreted by WJ-MSCs. Also, WJ-MSC cell lysates as well as the conditioned medium they are cultured in strongly inhibited the growth of breast adenocarcinoma, ovarian carcinoma, osteosarcoma, benign neoplastic keloid cells, bladder tumor, and lymphoma cells  in vitro. When WJ-MSC cell lysates and conditioned medium were injected into mammary carcinoma, osteosarcoma, and pancreatic and lung tumors it inhibited their growth and shrank the tumors in vivo .

WJ-MSCs DO NOT CAUSE IMMUNE REJECTION OR ADVERSE REACTIONS  

WJ-MSCs have also been found to be immunoprivileged which is to say they escape rejection or adverse immune reactions. Part of the reason for this lies in the fact WJ-MSCs have low MHC-I levels and an absence of MHC-II expression. And, though they synthesize low amounts of MHC class I, WJ-MSCs have no immunogenicity. Research indicates that this is due to the fact they  do not express costimulatory molecules such as CD 40, CD80, CD86, and also produce high levels of immune response inhibitors such as indoleamine-2,3-dioxygenase (IDO), prostaglandin E2 (PGE2) and leukocyte antigen G6 (HLA-G6).

NOVA CELLS INSTITUTE HARVESTS & MAKES CLINICAL USE OF STEM CELLS ISOLATED FROM (UMBILICAL CORD) WHARTON’S JELLY CELLS: https://ncimx.wordpress.com/2015/03/15/whartons-jelly-stem-cells/

ADDITIONAL REFERENCES – NIH PubMed results (5-1-2016)

Wharton’s Jelly-derived mesenchymal stem cells alleviate memory deficits and reduce amyloid-β deposition in an APP/PS1 transgenic mouse model.
Xie ZH, Liu Z, Zhang XR, Yang H, Wei LF, Wang Y, Xu SL, Sun L, Lai C, Bi JZ, Wang XY.
Clin Exp Med. 2016 Feb;16(1):89-98. doi: 10.1007/s10238-015-0375-0. Epub 2015 Jul 19.
PMID: 26188488 [PubMed – in process]
Similar articles

Therapeutic influence of intraperitoneal injection of Wharton’s jelly-derived mesenchymal stem cells on oviduct function and fertility in rats with acute and chronic salpingitis.
Luo HJ, Xiao XM, Zhou J, Wei W.
Genet Mol Res. 2015 Apr 17;14(2):3606-17. doi: 10.4238/2015.April.17.10.
PMID: 25966129 [PubMed – indexed for MEDLINE] Free Article
Similar articles

Effect of human Wharton’s jelly mesenchymal stem cell secretome on proliferation, apoptosis and drug resistance of lung cancer cells.
Hendijani F, Javanmard ShH, Rafiee L, Sadeghi-Aliabadi H.
Res Pharm Sci. 2015 Mar-Apr;10(2):134-42.
PMID: 26487890 [PubMed] Free PMC Article
Similar articles

Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells.
Carlsson PO, Schwarcz E, Korsgren O, Le Blanc K.
Diabetes. 2015 Feb;64(2):587-92. doi: 10.2337/db14-0656. Epub 2014 Sep 9.
PMID: 25204974 [PubMed – indexed for MEDLINE] Free Article
Similar articles

. The Potential of Wharton’s Jelly Derived Mesenchymal Stem Cells in Treating Patients with Cystic Fibrosis.
Boruczkowski D, Gładysz D, Demkow U, Pawelec K.
Adv Exp Med Biol. 2015;833:23-9. doi: 10.1007/5584_2014_17. Review.
PMID: 25248343 [PubMed – indexed for MEDLINE]
Similar articles

Wharton’s jelly derived mesenchymal stem cells: future of regenerative medicine? Recent findings and clinical significance.
Kalaszczynska I, Ferdyn K.
Biomed Res Int. 2015;2015:430847. doi: 10.1155/2015/430847. Epub 2015 Mar 15. Review.
PMID: 25861624 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

Undifferentiated Wharton’s Jelly Mesenchymal Stem Cell Transplantation Induces Insulin-Producing Cell Differentiation and Suppression of T-Cell-Mediated Autoimmunity in Nonobese Diabetic Mice.
Tsai PJ, Wang HS, Lin GJ, Chou SC, Chu TH, Chuan WT, Lu YJ, Weng ZC, Su CH, Hsieh PS, Sytwu HK, Lin CH, Chen TH, Shyu JF.
Cell Transplant. 2015;24(8):1555-70. doi: 10.3727/096368914X683016. Epub 2014 Jul 15.
PMID: 25198179 [PubMed – in process]
Similar articles

Effects of Wharton’s jelly-derived mesenchymal stem cells on neonatal neutrophils.
Khan I, Zhang L, Mohammed M, Archer FE, Abukharmah J, Yuan Z, Rizvi SS, Melek MG, Rabson AB, Shi Y, Weinberger B, Vetrano AM.
J Inflamm Res. 2014 Dec 31;8:1-8. doi: 10.2147/JIR.S71987. eCollection 2015.
PMID: 25678809 [PubMed] Free PMC Article
Similar articles

A comparison of Wharton’s jelly and cord blood as a source of mesenchymal stem cells for diabetes cell therapy.
El-Demerdash RF, Hammad LN, Kamal MM, El Mesallamy HO.
Regen Med. 2015;10(7):841-55. doi: 10.2217/rme.15.49. Epub 2015 Nov 6.
PMID: 26541176 [PubMed – in process]
Similar articles

. Comparisons of Differentiation Potential in Human Mesenchymal Stem Cells from Wharton’s Jelly, Bone Marrow, and Pancreatic Tissues.
Kao SY, Shyu JF, Wang HS, Lin CH, Su CH, Chen TH, Weng ZC, Tsai PJ.
Stem Cells Int. 2015;2015:306158. doi: 10.1155/2015/306158. Epub 2015 Jul 29.
PMID: 26294917 [PubMed] Free PMC Article
Similar articles

. Roles of the co-culture of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells with rat pancreatic cells in the treatment of rats with diabetes mellitus.
Wang G, Li Y, Wang Y, Dong Y, Wang FS, Ding Y, Kang Y, Xu X.
Exp Ther Med. 2014 Nov;8(5):1389-1396. Epub 2014 Sep 22.
PMID: 25289028 [PubMed] Free PMC Article
Similar articles

Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation.
Li X, Bai J, Ji X, Li R, Xuan Y, Wang Y.
Int J Mol Med. 2014 Sep;34(3):695-704. doi: 10.3892/ijmm.2014.1821. Epub 2014 Jun 25.
PMID: 24970492 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

Safety and feasibility of umbilical cord mesenchymal stem cells in treatment-refractory systemic lupus erythematosus nephritis: time for a double-blind placebo-controlled trial to determine efficacy.
Woodworth TG, Furst DE.
Arthritis Res Ther. 2014 Jul 30;16(4):113. doi: 10.1186/ar4677.
PMID: 25166210 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

A preliminary evaluation of efficacy and safety of Wharton’s jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus.
Liu X, Zheng P, Wang X, Dai G, Cheng H, Zhang Z, Hua R, Niu X, Shi J, An Y.
Stem Cell Res Ther. 2014 Apr 23;5(2):57. doi: 10.1186/scrt446.
PMID: 24759263 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton’s jelly.
Amable PR, Teixeira MV, Carias RB, Granjeiro JM, Borojevic R.
Stem Cell Res Ther. 2014 Apr 16;5(2):53. doi: 10.1186/scrt442.
PMID: 24739658 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

Therapeutic effect of transplanted human Wharton’s jelly stem cell-derived oligodendrocyte progenitor cells (hWJ-MSC-derived OPCs) in an animal model of multiple sclerosis.
Mikaeili Agah E, Parivar K, Joghataei MT.
Mol Neurobiol. 2014 Apr;49(2):625-32. doi: 10.1007/s12035-013-8543-2. Epub 2013 Aug 28.
PMID: 23982748 [PubMed – indexed for MEDLINE]
Similar articles

Microvesicles derived from human Wharton’s Jelly mesenchymal stromal cells ameliorate renal ischemia-reperfusion injury in rats by suppressing CX3CL1.
Zou X, Zhang G, Cheng Z, Yin D, Du T, Ju G, Miao S, Liu G, Lu M, Zhu Y.
Stem Cell Res Ther. 2014 Mar 19;5(2):40. doi: 10.1186/scrt428.
PMID: 24646750 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

. Effect of combined therapy of human Wharton’s jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats.
Hu J, Wang F, Sun R, Wang Z, Yu X, Wang L, Gao H, Zhao W, Yan S, Wang Y.
Endocrine. 2014 Mar;45(2):279-87. doi: 10.1007/s12020-013-9984-0. Epub 2013 May 18.
PMID: 23686639 [PubMed – indexed for MEDLINE]
Similar articles

Effect of human Wharton’s jelly mesenchymal stem cell paracrine signaling on keloid fibroblasts.
Arno AI, Amini-Nik S, Blit PH, Al-Shehab M, Belo C, Herer E, Jeschke MG.
Stem Cells Transl Med. 2014 Mar;3(3):299-307. doi: 10.5966/sctm.2013-0120. Epub 2014 Jan 16.
PMID: 24436441 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

Human Wharton’s jelly mesenchymal stem cells promote skin wound healing through paracrine signaling.
Arno AI, Amini-Nik S, Blit PH, Al-Shehab M, Belo C, Herer E, Tien CH, Jeschke MG.
Stem Cell Res Ther. 2014 Feb 24;5(1):28. doi: 10.1186/scrt417.
PMID: 24564987 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

. Characterization of hepatic markers in human Wharton’s Jelly-derived mesenchymal stem cells.
Buyl K, De Kock J, Najar M, Lagneaux L, Branson S, Rogiers V, Vanhaecke T.
Toxicol In Vitro. 2014 Feb;28(1):113-9. doi: 10.1016/j.tiv.2013.06.014. Epub 2013 Jun 29.
PMID: 23820183 [PubMed – indexed for MEDLINE]
Similar articles

Human Wharton’s Jelly Mesenchymal Stem Cells plasticity augments scar-free skin wound healing with hair growth.
Sabapathy V, Sundaram B, V M S, Mankuzhy P, Kumar S.
PLoS One. 2014 Apr 15;9(4):e93726. doi: 10.1371/journal.pone.0093726. eCollection 2014.
PMID: 24736473 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

Stem cells from umbilical cord Wharton’s jelly from preterm birth have neuroglial differentiation potential.
Messerli M, Wagner A, Sager R, Mueller M, Baumann M, Surbek DV, Schoeberlein A.
Reprod Sci. 2013 Dec;20(12):1455-64. doi: 10.1177/1933719113488443. Epub 2013 May 13.
PMID: 23670950 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

Wharton’s jelly-derived mesenchymal stem cells promote myocardial regeneration and cardiac repair after miniswine acute myocardial infarction.
Zhang W, Liu XC, Yang L, Zhu DL, Zhang YD, Chen Y, Zhang HY.
Coron Artery Dis. 2013 Nov;24(7):549-58. doi: 10.1097/MCA.0b013e3283640f00.
PMID: 23892469 [PubMed – indexed for MEDLINE]
Similar articles

Reduction of fibrosis in dibutyltin dichloride-induced chronic pancreatitis using rat umbilical mesenchymal stem cells from Wharton’s jelly.
Zhou CH, Li ML, Qin AL, Lv SX, Wen-Tang, Zhu XY, Li LY, Dong Y, Hu CY, Hu DM, Wang SF.
Pancreas. 2013 Nov;42(8):1291-302. doi: 10.1097/MPA.0b013e318296924e.
PMID: 24152954 [PubMed – indexed for MEDLINE]
Similar articles

Human Wharton’s jelly-derived mesenchymal stromal cells reduce renal fibrosis through induction of native and foreign hepatocyte growth factor synthesis in injured tubular epithelial cells.
Du T, Zou X, Cheng J, Wu S, Zhong L, Ju G, Zhu J, Liu G, Zhu Y, Xia S.
Stem Cell Res Ther. 2013 Jun 4;4(3):59. doi: 10.1186/scrt215.
PMID: 23734757 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

Higher propensity of Wharton’s jelly derived mesenchymal stromal cells towards neuronal lineage in comparison to those derived from adipose and bone marrow.
Balasubramanian S, Thej C, Venugopal P, Priya N, Zakaria Z, Sundarraj S, Majumdar AS.
Cell Biol Int. 2013 May;37(5):507-15. doi: 10.1002/cbin.10056. Epub 2013 Feb 18.
PMID: 23418097 [PubMed – indexed for MEDLINE]
Similar articles

Immunosuppressive properties of mesenchymal stromal cells derived from amnion, placenta, Wharton’s jelly and umbilical cord.
Manochantr S, U-pratya Y, Kheolamai P, Rojphisan S, Chayosumrit M, Tantrawatpan C, Supokawej A, Issaragrisil S.
Intern Med J. 2013 Apr;43(4):430-9. doi: 10.1111/imj.12044.
PMID: 23176558 [PubMed – indexed for MEDLINE]
Similar articles

. Mesenchymal stem cells derived from Wharton’s Jelly of the umbilical cord: biological properties and emerging clinical applications.
Batsali AK, Kastrinaki MC, Papadaki HA, Pontikoglou C.
Curr Stem Cell Res Ther. 2013 Mar;8(2):144-55. Review.
PMID: 23279098 [PubMed – indexed for MEDLINE]
Similar articles

Proangiogenic features of Wharton’s jelly-derived mesenchymal stromal/stem cells and their ability to form functional vessels.
Choi M, Lee HS, Naidansaren P, Kim HK, O E, Cha JH, Ahn HY, Yang PI, Shin JC, Joe YA.
Int J Biochem Cell Biol. 2013 Mar;45(3):560-70. doi: 10.1016/j.biocel.2012.12.001. Epub 2012 Dec 12.
PMID: 23246593 [PubMed – indexed for MEDLINE]
Similar articles

Mesenchymal stem cells isolated from peripheral blood and umbilical cord Wharton’s jelly.
Trivanović D, Kocić J, Mojsilović S, Krstić A, Ilić V, Djordjević IO, Santibanez JF, Jovcić G, Terzić M, Bugarski D.
Srp Arh Celok Lek. 2013 Mar-Apr;141(3-4):178-86.
PMID: 23745340 [PubMed – indexed for MEDLINE] Free Article
Similar articles

Wharton’s jelly or bone marrow mesenchymal stromal cells improve cardiac function following myocardial infarction for more than 32 weeks in a rat model: a preliminary report.
López Y, Lutjemeier B, Seshareddy K, Trevino EM, Hageman KS, Musch TI, Borgarelli M, Weiss ML.
Curr Stem Cell Res Ther. 2013 Jan;8(1):46-59.
PMID: 23270633 [PubMed – indexed for MEDLINE]
Similar articles

Perspectives of employing mesenchymal stem cells from the Wharton’s jelly of the umbilical cord for peripheral nerve repair.
Ribeiro J, Gartner A, Pereira T, Gomes R, Lopes MA, Gonçalves C, Varejão A, Luís AL, Maurício AC.
Int Rev Neurobiol. 2013;108:79-120. doi: 10.1016/B978-0-12-410499-0.00004-6. Review.
PMID: 24083432 [PubMed – indexed for MEDLINE]
Similar articles

Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis.
Hsieh JY, Wang HW, Chang SJ, Liao KH, Lee IH, Lin WS, Wu CH, Lin WY, Cheng SM.
PLoS One. 2013 Aug 22;8(8):e72604. doi: 10.1371/journal.pone.0072604. eCollection 2013.
PMID: 23991127 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

Comparison of mesenchymal stem cells derived from fat, bone marrow, Wharton’s jelly, and umbilical cord blood for treating spinal cord injuries in dogs.
Ryu HH, Kang BJ, Park SS, Kim Y, Sung GJ, Woo HM, Kim WH, Kweon OK.
J Vet Med Sci. 2012 Dec;74(12):1617-30. Epub 2012 Aug 9.
PMID: 22878503 [PubMed – indexed for MEDLINE] Free Article
Similar articles

Hydrogen peroxide preconditioning enhances the therapeutic efficacy of Wharton’s Jelly mesenchymal stem cells after myocardial infarction.
Zhang J, Chen GH, Wang YW, Zhao J, Duan HF, Liao LM, Zhang XZ, Chen YD, Chen H.
Chin Med J (Engl). 2012 Oct;125(19):3472-8.
PMID: 23044308 [PubMed – indexed for MEDLINE] Free Article
Similar articles

Immune characterization of mesenchymal stem cells in human umbilical cord Wharton’s jelly and derived cartilage cells.
Liu S, Yuan M, Hou K, Zhang L, Zheng X, Zhao B, Sui X, Xu W, Lu S, Guo Q.
Cell Immunol. 2012 Jul-Aug;278(1-2):35-44. doi: 10.1016/j.cellimm.2012.06.010. Epub 2012 Jul 16.
PMID: 23121974 [PubMed – indexed for MEDLINE]
Similar articles

Human umbilical cord Wharton’s jelly mesenchymal stem cells do not transform to tumor-associated fibroblasts in the presence of breast and ovarian cancer cells unlike bone marrow mesenchymal stem cells.
Subramanian A, Shu-Uin G, Kae-Siang N, Gauthaman K, Biswas A, Choolani M, Bongso A, Chui-Yee F.
J Cell Biochem. 2012 Jun;113(6):1886-95. doi: 10.1002/jcb.24057.
PMID: 22234854 [PubMed – indexed for MEDLINE]
Similar articles

Comparison of human amniotic fluid-derived and umbilical cord Wharton’s Jelly-derived mesenchymal stromal cells: Characterization and myocardial differentiation capacity.
Bai J, Hu Y, Wang YR, Liu LF, Chen J, Su SP, Wang Y.
J Geriatr Cardiol. 2012 Jun;9(2):166-71. doi: 10.3724/SP.J.1263.2011.12091.
PMID: 22916064 [PubMed] Free PMC Article
Similar articles

Immunosuppressive function of mesenchymal stem cells from human umbilical cord matrix in immune thrombocytopenia patients.
Ma L, Zhou Z, Zhang D, Yang S, Wang J, Xue F, Yang Y, Yang R.
Thromb Haemost. 2012 May;107(5):937-50. doi: 10.1160/TH11-08-0596. Epub 2012 Mar 8.
PMID: 22398715 [PubMed – indexed for MEDLINE]
Similar articles

Comparison of chemokine and receptor gene expression between Wharton’s jelly and bone marrow-derived mesenchymal stromal cells.
Balasubramanian S, Venugopal P, Sundarraj S, Zakaria Z, Majumdar AS, Ta M.
Cytotherapy. 2012 Jan;14(1):26-33. doi: 10.3109/14653249.2011.605119. Epub 2011 Nov 18.
PMID: 22091833 [PubMed – indexed for MEDLINE]
Similar articles

Wharton’s Jelly stem cells: future clinical applications.
Taghizadeh RR, Cetrulo KJ, Cetrulo CL.
Placenta. 2011 Oct;32 Suppl 4:S311-5. doi: 10.1016/j.placenta.2011.06.010. Epub 2011 Jul 6. Review.
PMID: 21733573 [PubMed – indexed for MEDLINE]
Similar articles

Neuronal plasticity of human Wharton’s jelly mesenchymal stromal cells to the dopaminergic cell type compared with human bone marrow mesenchymal stromal cells.
Datta I, Mishra S, Mohanty L, Pulikkot S, Joshi PG.
Cytotherapy. 2011 Sep;13(8):918-32. doi: 10.3109/14653249.2011.579957. Epub 2011 Jun 22.
PMID: 21696238 [PubMed – indexed for MEDLINE]
Similar articles

Wharton’s jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes.
Anzalone R, Lo Iacono M, Loria T, Di Stefano A, Giannuzzi P, Farina F, La Rocca G.
Stem Cell Rev. 2011 Jun;7(2):342-63. doi: 10.1007/s12015-010-9196-4. Review.
PMID: 20972649 [PubMed – indexed for MEDLINE]
Similar articles

Immunomodulatory effect of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells on lymphocytes.
Zhou C, Yang B, Tian Y, Jiao H, Zheng W, Wang J, Guan F.
Cell Immunol. 2011;272(1):33-8. doi: 10.1016/j.cellimm.2011.09.010. Epub 2011 Sep 29.
PMID: 22004796 [PubMed – indexed for MEDLINE] Free PMC Article
Similar articles

Read this before you settle on a stem cell or other treatment or therapy in Mexico or elsewhere

E-MAIL Free MS imageNova Cells Institute (NCIM) often gets emails from people who ask about stem cell and other therapies done elsewhere but which have little chance of turning things around for them. Here are some of these treatments along with comments by NCIM experts:

(1) Subcutaneous injections of stem cells to treat serious neurologic and other health challenges, including cancer. COMMENT: Subcutaneously injected stem cells may stimulate production of nerve growth factor or other compounds, but is an iffy way to stimulate healing or regeneration unless one is treating a problem very close to the injection site. Depending on the target tissue or organ, stem cells given by intravenous, intrathecal or other routes is more likely to have the desired therapeutic effect.

(2)  Nova Cells hears from people who have been told that biochemical signals from injured or diseased tissues will attract infused stem cells. This is true but what they aren’t being told is that these signals fade over time or the injected or infuse stem cells typically do not respond fully to them. COMMENT: Nova Cells director of laboratory services, Dr. Abel Pena, created a nontoxic homing/signal amplification (or “beacon”) compound that stimulates damaged or diseased tissues to send out stronger stem cell attractive signals while simultaneously sensitizing stem cells to recognize and respond to these signals. This compound was dubbed, appropriately enough, the “Beacon Factor” and positively no one has it or anything like it but Nova Cells. You can read more about it by clicking this link.

3) Emails occasionally come in from people saying they have been offered some kind of stem cell or other therapy (for a serious or intractable condition) in Mexico or elsewhere for between $1,000-4,000 USD. COMMENT: The old sayings “If it sounds too good to be true, it is” and “caveat emptor” (Buyer beware) certainly applies here. What NCIM has turned up down through the years (with respect to these “medical blue plate specials”) are instances in which: (a) MDs and others gave patients far fewer cells than claimed. In one particular instance, an office worker in a so-called stem cell clinic reported actually seeing a doctor take a vial labelled as containing 5 million umbilical cord stem cells and placing a small quantity from this into each of ten other vials, then administering these to patients who had paid to get 5 million stem cells each; (b) Patients were given “live cell therapy” (embryonic cells from animals typically lambs) but were told  they were getting human umbilical or other adult stem cells: (c) People with advanced, terminal cancer were given low cost treatments that had worked in lab dish or animal studies but bombed out in well designed & executed studies done in humans.

Doing medicine in Mexico is not cheap contrary to what some people think. Unfortunately, there are unscrupulous doctors and clinics that have come up with “cost cutting measures” (like those above) who do a grave disservice to the patients they purport to help.

Abel at lab cabinetNova Cells is able to offer economically priced care, i.e., typically 30% less than other stem cell medicine operations, because it cut out the “middle men”, e.g., professional marketers and public relations people, and was able to get top flight MDs including surgeons on board who believe profits must take a backseat to getting people well. And, its head of laboratory services, Dr. Abel Pena (photo on right), who was trained (in part) by a leading US stem cell biologist, insists on processing & counting all stem cells himself and then priming or programming them (to become cell types that are more likely to effect healing or restoration in a given patient than unprimed stem cells). Dr. Pena personally handles all aspects of stem cell and Beacon Factor processing so as to insure that everything is done to the highest cGMP (manufacturing) standards and the patient is getting exactly what he or she paid for.

SKY BLUE E-BOOK COVER FOR HEROIC MEDICINENova Cells has assembled information on its stem cell medicine program including stem cell priming and its proprietary Beacon Factor in e-book form titled  “Heroic Medicine” which is free at http://www.novacellsinstitute.com/pdf/Heroic%20Medicine.pdf

Stem cell homing = Better clinical outcomes

Stem cell homing makes a big difference in clinical outcomes. Watch this short video to learn more about how Nova Cells pulls this off.  

Nova Cells Institute gets stem cells to target tissues using its Beacon Factor. Learn more by getting our FREE e-book “Heroic Medicine” (Click to download). Read about our successful stem cell treatments for spina bifida, cancer, stroke, dementia, autoimmune diseases, and more. Get your FREE e-book “Heroic Medicine” now!

You’ve got to get stem cells to their target tissue or organ. No one but Nova Cells has a way to reliably pull this off.

DART BOARD - Free MorguefileIf you ever played the game of darts or used a crossbow you know the goal is to hit your target. In the world of stem cell medicine the same holds true. Virtually all stem cell therapy clinics and hospitals infuse or inject stem cells and count on biochemical signals produced by damaged or diseased tissues to “get the darts” (stem cells) to target. This works in principle, yes, but likely winds up with more stem cells lodged in non-target tissues than in the tissues or organ needing healing or restoration. This diminishes responses and outcomes as you would expect.

SONY DSC

But what if you switch on a homing system in the stem cells and amplify the signals in diseased or damaged tissues or organs? More “darts” or “biologic missiles” (stem cells) will hit their mark!

No stem cell clinic or such anywhere has a biologic “guidance & homing signal amplification system” that helps get stem cells to target. None, that is, but Nova Cells Institute which pulls this off thanks to its proprietary Beacon Factor. You can read more about the Beacon Factor by clicking this link.

You will also find information on the Beacon Factor in Nova Cells Institute’s  just published e-book titled “Heroic Medicine”, which is free for downloading at http://www.novacellsinstitute.com/pdf/Heroic%20Medicine.pdf

Julia Simpson’s eye, bladder and Parkinson’s symptoms disappeared quickly following Nova Cells treatment

E-MAIL Free MS imageEmailed to Nova Cells:

This is Julia Simpson. I heard about Nova Cells Institute from other patients so I looked them up and checked out their website and testimonials. I am getting on in years being 66 and just feel the weight of the years on me. I have been pretty much healthy all of my life but as the years passed by I acquired more and more little problems which latter turn chronic. I get check-ups, take supplements, but my symptoms persisted.

I have a prolapsed bladder which makes me get up at night at least 2 times sometimes three times. This has been going on for about 6 years.

About 8 years ago a doctor prescribed Calcitonin as a nasal spray to avoid bone loss. I used it for about a month and a half. About a month into it I started to have problems with my right eye. It began tearing during the night and I had pain in it and it was red and irritated. Then headache started on that side. I did not connect this to the nasal spray. For days I had the tearing and redness even during the day and became very sensitive to sunlight. I realized that I was putting the spray in my right nostril, and the right eye was the one giving me a problem. So  I then stopped using it and told my doctor.  The problem is that although it stopped bothering me during the day it has never stopped giving me problems at night if I sleep on the right side, and I still had lots of pain.

I have more or less a lot of energy but I take one or two small naps a day to get reenergized.

One major thing that has been bothering me for the last 6 years is that my right hand is trembling slightly, some times more so when I get stressed. I got very worried about having Parkinson’s. I decided to get a stem cell treatment for rejuvenating my organs and hopefully helping get rid myself of the Parkinson’s like symptoms because although it is not progressing it does not go away and left me very worried about this.

On June 19, 2015 I had my stem cell treatment at NCIM . I was picked up by Abel and Grace who were so nice and professional. They answered all of my questions so I felt at ease and relaxed because I went to Mexico alone.

The city of Tijuana was just around the corner sort of speak. Just 15 minutes from the city of San Diego. The city itself was totally different from what I had imagined. It is a real nice city of 3 million people. They have roundabouts often and lots of statues of heroes, even one of Abraham Lincoln  (planted in the avenue of the heroes). I understand the Lincoln statue serves as a “thumbs up” to American democracy and is a “welcome here” for US tourists. Lots of beautiful tall buildings, many made of all glass, dot the landscape everywhere.  I saw McDonald’s, Costco, Office Max, Office Depot, Walmart, and a Subway Sandwich shop among others.  People were milling about and walking all over the place, kind of like New York. I felt really good about Tijuana and totally safe.

Once I got to the hospital I found the staff incredibly friendly and courteous. Once I got checked in I was assessed by three doctors an internal medicine as well as a neurologist and an anesthesiologist.

The doctors did many tests and then I was infused with the Beacon Factor and got my stem cells by IV and also a percentage by spinal tap. I was not put to sleep for my spinal tap. The MDs just gave me a local anesthesia where the little puncture was made. It didn’t hurt at all. Then I got more Beacon Factor which helps the stem cells seek out damaged tissue. I was there for observation for a few hours then discharged. Abel and Grace then took me to eat at a delicious cafeteria with all kinds of Mexican dishes to choose from. Then was brought back across the border in the US.

About 6 days after my treatment all of a sudden I noticed that my eye no longer was tearing up or hurt any more. I could not believe it and decided to wait a few more days just in case it came back. It has already been 17 days and the eye is not tearing up.

My energy has shot up incredibly too. To the point where I’ve only taken naps three times in all these days, and short ones at that.

About a week into my treatment I noticed that I was not waking up at night to go to the bathroom. I was instead sleeping through the night like a baby and waking up at 8:00 or 8:30 AM each morning. I wake up so rested. I am going into deep sleep every night and am even dreaming now which was not true in the past.

My bladder, of course, is still prolapsed, but I do not have the sensation of needing to visit the bathroom over and over again each night.

But the most wonderful thing is that my hand shaking is all gone and I am ecstatic about this! About 10 days post-treatment, I was using my computer when I realized that I was not shaking any more. Of all the symptoms impacted by my treatment I am so happy and amazed that the shaking is gone! It was amazing that I felt so good I did not even notice the change at first. Thank you Nova Cells Institute! Yes, I was hoping to get rid of my Parkinson’s symptoms, but I never thought that they would be gone in a matter of days. Maybe it was so quick because my shaking was rather mild,  but even if it had taken months I would have been just as happy.  I am not afraid or concerned any more.

Julia Simpson